Can Hims & Hers Health stock sustain rebound as immediate support holds?

Traders Union
All News
Stocks
Hims & Hers Health jumps 3.79% today

Highlights

Hims & Hers Health faces a lawsuit by the FTC and state regulators charging deceptive privacy and billing practices, including alleged improper sharing of medical data and limiting cancellation options.
A securities fraud class action was filed in California federal court alleging the company misrepresented its business practices and regulatory risks to investors.
Hims & Hers Health stock gained 3.79% to $30.43 with strong bullish momentum, expected to trade between $28.55 and $32.31 over the next few days.

Twin lawsuits increase legal risks amid regulatory scrutiny

On July 29, 2026, the Federal Trade Commission, together with California and Utah regulators, filed a lawsuit against Hims & Hers Health, Inc. over alleged deceptive privacy, billing, and subscription practices, including claims of improperly sharing customer medical data and restricting cancellation options, according to Financialcontent. This regulatory action raises legal and reputational risks, potentially increasing future compliance costs and impacting investor confidence. Additionally, a securities fraud class action was filed in federal court in California, with allegations that the company misrepresented its business practices and regulatory risks, as reported by Prnewswire. The twin legal challenges introduce fresh overhangs at a time of heightened regulatory scrutiny for the company.

Buy signals strengthen as price exceeds multiple technical levels

On the technical side, HIMS is trading above the MA-20 at $29.24 and MA-50 at $28.66 on the hourly chart, and it remains above the MA-200 at $27.91 on the daily chart. The Ichimoku Kijun sits at $29.75, serving as immediate support. Both ADX and MACD signal Buy, with the RSI at 64.65 also indicating upward momentum. CCI is bullish, while Stochastic RSI is neutral and the Awesome Oscillator remains neutral. Bull/Bear Power is overbought, pointing to aggressive buyer activity dominating the intraday tape.

Rangebound outlook persists as momentum tempers reversal risk

Over the coming sessions, price is likely to fluctuate within the $28.551732.31 range, reflecting typical volatility. The baseline scenario calls for HIMS to remain within this corridor, with a breakout above resistance opening the door for further gains. Conversely, a decisive move below immediate support would indicate a potential reversal toward lower levels, but the probability of sustained downside remains low given the prevailing momentum.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health trading with strong momentum despite facing major legal and regulatory headwinds. He believes the stock’s technical strength and upward trend dominate near-term sentiment, even as lawsuits from the FTC and investors cloud the macro outlook. Karapetjanc notes that increasing compliance costs and reputational risks could affect future performance, but buyers remain in control for now. "Regulatory risks are rising, but as long as HIMS holds above key moving averages, the bullish trend should persist in the short term."

Earlier, analysts noted that while Hims & Hers Health displayed strong bullish momentum, overbought technical signals and emerging legal risks could moderate further gains. The current analysis introduces significant new regulatory and litigation overhangs, making upcoming reactions to resistance levels and headline risk critical for traders monitoring the stock’s direction.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.